Abstract
| Language | English |
|---|---|
| Article number | 1482 |
| Pages | 1-10 |
| Number of pages | 10 |
| Journal | Nature Communications |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 16 Apr 2018 |
| Externally published | Yes |
Fingerprint
Bibliographical note
Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Cite this
}
Characterising the phenotypic evolution of circulating tumour cells during treatment. / Tsao, Simon Chang Hao; Wang, Jing; Wang, Yuling; Behren, Andreas; Cebon, Jonathan; Trau, Matt.
In: Nature Communications, Vol. 9, No. 1, 1482, 16.04.2018, p. 1-10.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Characterising the phenotypic evolution of circulating tumour cells during treatment
AU - Tsao,Simon Chang Hao
AU - Wang,Jing
AU - Wang,Yuling
AU - Behren,Andreas
AU - Cebon,Jonathan
AU - Trau,Matt
N1 - Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2018/4/16
Y1 - 2018/4/16
N2 - Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.
AB - Real-time monitoring of cancer cells’ phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as “cell signature”), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.
UR - http://purl.org/au-research/grants/arc/DE140101056
UR - http://www.scopus.com/inward/record.url?scp=85045583786&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-03725-8
DO - 10.1038/s41467-018-03725-8
M3 - Article
VL - 9
SP - 1
EP - 10
JO - Nature Communications
T2 - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
M1 - 1482
ER -